Azura Ophthalmics
PrivateLast Round
Series C
Oct 22, 2020
Total Funding Raised
$37.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Azura Ophthalmics operates in Healthcare & Life Sciences and is based in Tel Aviv. Its latest recorded funding round was a Series C round in October 2020.
Azura Ophthalmics is a clinical-stage biopharmaceutical company developing a new class of Ophthalmic Keratolytics for the treatment of Meibomian gland dysfunction (MGD) and other ocular surface diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Azura Ophthalmics Comparables
Compare Azura Ophthalmics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Novaliq | 84% | |
| Stuart Therapeutics, Inc. | 77% | |
| Aldeyra Therapeutics | 76% |
For institutional investors. Book with your work email.
Azura Ophthalmics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 22, 2020 | ||||
| Series B | Oct 10, 2017 | ||||
| Series A | Mar 11, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Azura Ophthalmics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ganot Capital | Series B, Series A, Series C |
| OrbiMed | Series B, Series C |
| TPG Biotech | Series B, Series C |
| Elron Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 5304% MoM, from 25 to 1.4K.
- May 1, 2025
Monthly visitors increased 77% MoM.
For institutional investors. Book with your work email.
Azura Ophthalmics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Azura Ophthalmics's valuation, stock price, and market status.
Is Azura Ophthalmics a public or private company?
Azura Ophthalmics is a private company.
What is the current stock price of Azura Ophthalmics?
Azura Ophthalmics is a private company, so its shares have no public market price. Caplight tracks Azura Ophthalmics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Azura Ophthalmics worth (valuation)?
Valuation information for Azura Ophthalmics is not publicly available.
Can I buy Azura Ophthalmics stock?
Azura Ophthalmics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Azura Ophthalmics's last funding round?
Azura Ophthalmics's most recent funding round was Series C on October 22, 2020.
Who are the main investors in Azura Ophthalmics?
Key investors in Azura Ophthalmics include Ganot Capital, OrbiMed, TPG Biotech.
Will Azura Ophthalmics IPO soon?
No public IPO plans have been announced for Azura Ophthalmics.
How can I track Azura Ophthalmics secondary market activity?
Caplight tracks bids, offers, and trades in Azura Ophthalmics's shares on secondary markets.